Cencora

(New York Stock Exchange)
Back to all articles
Slightly Bullish +15

Arcus Capital Partners LLC Takes $678,000 Position in Cencora, Inc ...

AI-generated analysis

πŸ“ˆ Arcus Capital Partners LLC purchased a new position in Cencora valued at approximately $678,000 during the first quarter.

πŸ“‰ Barclays and Robert W. Baird recently cut their price targets to $350.00 and $339.00 respectively, while Weiss Ratings downgraded the stock from 'buy' to 'hold'.

πŸ’° Cencora reported Q1 revenue of $78.36 billion, a 3.9% increase year-over-year, though it missed analyst EPS estimates by $0.07.

πŸ”„ The company's Board of Directors approved a new $2.00 billion share repurchase program authorized on May 21st.

πŸ’΅ Investors received a quarterly dividend of $0.60 per share paid on June 1st, representing an annualized yield of 0.8%.

πŸ“Š The stock currently trades with a market cap of $59.87 billion and a PE ratio of 23.60, trading above its 50-day moving average.

πŸ‘₯ Director Lauren M. Tyler increased her personal stake by 14.44% in June, purchasing 550 shares for a total transaction of $148,626.50.

πŸ“ˆ Hedge funds and institutional investors own 97.52% of Cencora's outstanding stock as of the latest filings.

Bullish Signals
  • Cencora announced a $2.00 billion share repurchase program, signaling management's confidence in the stock's undervaluation and commitment to returning capital to shareholders.
  • The company reported revenue growth of 3.9% year-over-year to $78.36 billion, demonstrating continued expansion in its pharmaceutical distribution business despite missing EPS estimates.
  • Institutional ownership remains extremely high at 97.52%, with multiple new investors like Arcus Capital and Kemnay Advisory initiating positions in the first and fourth quarters.
  • The stock trades above its 50-day moving average of $279.98, suggesting short-term technical strength despite being below its 200-day moving average.
Risk Factors
  • Cencora missed Q1 analyst EPS estimates by $0.07, reporting $4.75 compared to the consensus of $4.82.
  • Revenue of $78.36 billion fell short of analyst expectations of $81.09 billion for the quarter.
  • Several major analysts recently lowered price targets, with Barclays cutting from $425 to $350 and Robert W. Baird reducing their target to $339.
  • Weiss Ratings downgraded the stock from a 'buy (b-)' rating to a 'hold (c+)' rating in late June.
Full Analysis
Arcus Capital Partners LLC established a new $678,000 position in Cencora, Inc. (NYSE:COR) during the first quarter, joining several other institutional investors like Kemnay Advisory and Oakworth Capital who also initiated or increased stakes in the fourth quarter. Hedge funds collectively own 97.52% of the company's stock, indicating significant institutional interest despite recent analyst rating adjustments. Analyst sentiment remains mixed with a consensus 'Moderate Buy' rating and an average price target of $367.75. While Morgan Stanley and Evercore maintain bullish targets around $342-$360, Barclays and Robert W. Baird recently lowered their price targets to $350 and $339 respectively, and Weiss Ratings downgraded the stock from a 'buy' to a 'hold'. Financially, Cencora reported Q1 EPS of $4.75, missing analyst estimates by $0.07, with revenue of $78.36 billion growing 3.9% year-over-year but falling short of the $81.09 billion consensus. The company has set FY 2026 guidance between $17.65 and $17.90 EPS, slightly below analyst predictions of $17.79. The company announced a $2.00 billion share repurchase program approved by its Board of Directors on May 21st, allowing the purchase of up to 3.9% of outstanding shares. Additionally, Cencora paid a quarterly dividend of $0.60 per share on June 1st, with an annualized yield of 0.8% and a payout ratio of 18.40%.